ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Apr 17, 2024
ASML Reports First Quarter Results, Reiterates Guidance
Image: ASML Holding is one of our favorite semiconductor ideas. On April 17, ASML Holding reported decent first quarter 2024 results. First quarter net sales came in at €5.29 billion on a gross margin of 51.0%. Net income was €1.22 billion in the quarter. Net bookings in the first quarter of 2024 came in at €3.6 billion, down sequentially from the strong net bookings number delivered in the fourth quarter of 2023. The company continues to be shareholder friendly, paying dividends and buying back €400 million worth of stock during the first quarter. Though management expects 2024 total net sales to be similar to 2023, we like how ASML is positioned for the long run.
Apr 16, 2024
Johnson & Johnson Narrows 2024 Outlook, Raises Dividend
Image Source: J&J. Looking to 2024, J&J expects adjusted operational sales growth in the range of 5.5%-6%, the midpoint of which is up from the prior range of 5%-6%. Adjusted operational diluted earnings per share is targeted in the range of $10.60-$10.75 per share, the midpoint also up from the range of $10.55-$10.75 previously. Management also upped its dividend 4.2%, to a quarterly payout of $1.24 per share, implying a forward estimated dividend yield of 3.4%. We like J&J, but we won’t be adding it back to any newsletter portfolio anytime soon.
Apr 15, 2024
Goldman Sachs Delivers in First Quarter
Image Source: Goldman Sachs. Goldman Sachs put up solid first-quarter 2024 results across all lines of its business, revealing that capital markets activity remains very healthy, even in the face of elevated interest rates. Goldman Sachs' book value per share was $321.10 at the end of the first quarter, revealing that shares are trading at 1.25x book at the time of this writing.
Apr 13, 2024
Vertex Pharma to Acquire Alpine Immune Services
Image: Vertex Pharma’s shares have had a nice run the past couple years. On April 10, Vertex Pharma announced that it had entered into an agreement where Vertex will acquire Alpine Immune Services for $65 per share or ~$4.9 billion in cash. We have no qualms with the deal for Alpine, and we expect Vertex Pharma to continue to deliver for shareholders.
Apr 11, 2024
Fastenal Puts Up Mixed First Quarter Results
Image: Fastenal reported mixed first quarter 2024 results. We like its business model quite a bit. On April 11, Fastenal Company reported mixed first-quarter fiscal 2024 results with revenue and earnings per share coming in slightly lower than expectations. Net sales advanced 1.9% for the three-month period ending March 31. The company noted that adverse weather impacted sales in its first quarter by about 10 to 30 basis points on a net basis. Operating income nudged lower in the quarter modestly, while net income advanced 0.9% in the period on a year-over-year basis. Diluted earnings per share was roughly flat in the quarter on a year-over-year basis, increasing 0.6% from the same period a year ago. We like Fastenal’s business model quite a bit, and shares yield ~2.1% at the time of this writing.
Apr 10, 2024
Delta Reports Strong March Quarter; Airline Stocks are Too Risky for Our Taste
Image Source: Colin Brown. Delta’s quarter ending in March was solid, and its full year outlook was encouraging. In general, however, we don’t like airline equities. The extreme ticket price transparency creates an ultra-competitive environment, and overcapacity is always a concern. We view airlines as merely trading vehicles on the health of the global economy and the trajectory of crude oil prices. Delta is operating well, but it will never be able to escape the challenges of its industry, and for those reasons we remain on the sidelines with respect to shares.
Apr 6, 2024
Crown Castle Under Activist Fire
Image: Crown Castle's shares have been under pressure the past couple years. Crown Castle continues to deal with activist pressure from Elliott Investment and founder Ted Miller (Boots Capital Management).
Apr 5, 2024
Dividend Increases/Decreases for the Week of April 5
Let's take a look at firms raising/lowering their dividends this week.
Apr 4, 2024
ConAgra’s ESG Initiatives Noble; Near-5% Dividend Yield Supported By Free Cash Flow
Image Source: ConAgra. ConAgra’s third-quarter fiscal 2024 results were decent, with the company showcasing strong free cash flow generation and further debt reduction. Year-to-date free cash flow at ConAgra totaled ~$1.2 billion versus $436 million during the same period a year ago. Cash dividends paid were $492 million over the same time, so ConAgra is doing a good job covering its dividend obligations with traditional free cash flow. We view this as a distinct positive for a company yielding ~4.8% at the time of this writing and think ConAgra is a consideration for investors seeking free-cash-flow covered yields and strong ESG initiatives.
Apr 3, 2024
Gilead’s 4%+ Dividend Yield Covered Nicely with Free Cash Flow
Image: Gilead’s coverage of its dividend with free cash flow remains rock-solid. What we like about Gilead is that the company remains a very strong free cash flow generator, with the measure coming in at $7.4 billion during 2023 versus dividend payments of $3.8 billion. On a free cash flow coverage basis, Gilead 4%+ dividend yield looks rock-solid, and for this, we think investors may be wise to get paid to wait for upcoming catalysts within Gilead’s HIV and oncology pipeline.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.